Placebo Response in Fragile X‐associated Tremor/Ataxia Syndrome

Fragile X‐associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder characterized by intention tremor, cerebellar ataxia, and executive dysfunction in carriers of a CGG repeat expansion premutation (55–200 repeats) in the fragile X mental retardation 1 (FMR1) gene. Given reports of poor insight in FXTAS, we postulated that patients with FXTAS would be less likely to exhibit placebo response.

[1]  G. Stebbins,et al.  Clinimetric Properties of the Fragile X‐associated Tremor Ataxia Syndrome Rating Scale , 2019, Movement disorders clinical practice.

[2]  G. Stebbins,et al.  What influences placebo and nocebo responses in Parkinson's disease? , 2018, Movement disorders : official journal of the Movement Disorder Society.

[3]  G. Casadesus,et al.  Memantine for the Treatment of Dementia: A Review on its Current and Future Applications , 2017, Journal of Alzheimer's disease : JAD.

[4]  María Campos-Magdaleno,et al.  Longitudinal Assessment of Verbal Learning and Memory in Amnestic Mild Cognitive Impairment: Practice Effects and Meaningful Changes , 2017, Front. Psychol..

[5]  C. Giulivi,et al.  Warburg effect linked to cognitive‐executive deficits in FMR1 premutation , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. Bourgeois,et al.  Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning , 2016, The Clinical neuropsychologist.

[7]  Fabrizio Benedetti,et al.  Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects , 2016, The Lancet Neurology.

[8]  T. O. Investigators.  Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy , 2016 .

[9]  C. Badenas,et al.  Skewed X Inactivation in Women Carrying the FMR1 Premutation and Its Relation with Fragile-X-Associated Tremor/Ataxia Syndrome , 2015, Neurodegenerative Diseases.

[10]  D. Hall,et al.  New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype , 2014, Front. Genet..

[11]  R. Yoash-Gantz,et al.  The Behavioral Dyscontrol Scale-II with non-elderly veterans. , 2014, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[12]  D. Nguyen,et al.  Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial. , 2014, The Journal of clinical psychiatry.

[13]  H. Singer,et al.  Impact of placebo assignment in clinical trials of tic disorders , 2013, Movement disorders : official journal of the Movement Disorder Society.

[14]  R. Jütte.  The early history of the placebo. , 2013, Complementary therapies in medicine.

[15]  M. Harciarek,et al.  Self‐awareness of executive dysfunction in Huntington's disease: Comparison with Parkinson's disease and cervical dystonia , 2013, Psychiatry and clinical neurosciences.

[16]  J. D. de Yébenes,et al.  Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[17]  D. Nguyen,et al.  Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. , 2010, Journal of clinical psychopharmacology.

[18]  H. Ehrenreich,et al.  Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing , 2010, BMC Neuroscience.

[19]  C. McDougle,et al.  Open-Label Memantine in Fragile X Syndrome , 2009, Journal of autism and developmental disorders.

[20]  Lin Zhang,et al.  Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems , 2008, Clinical interventions in aging.

[21]  Meghan B. Mitchell,et al.  Executive Functioning and Observed Versus Self-Reported Measures of Functional Ability , 2008, The Clinical neuropsychologist.

[22]  S. Leurgans,et al.  Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions , 2008, Movement disorders : official journal of the Movement Disorder Society.

[23]  Lin Zhang,et al.  Progression of tremor and ataxia in male carriers of the FMR1 premutation , 2007, Movement disorders : official journal of the Movement Disorder Society.

[24]  W. Brown,et al.  Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. , 2003, American journal of human genetics.

[25]  T. Ross.  The reliability of cluster and switch scores for the controlled oral word association test , 2003 .

[26]  R. Wilson,et al.  Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X , 2001, Neurology.

[27]  S. Leurgans,et al.  Objective changes in motor function during placebo treatment in PD , 2000, Neurology.

[28]  P. Hagerman,et al.  Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. , 2008, Neuropsychology.

[29]  D. Munoz.  Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. , 2002, Neurology.